| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1111/J.1526-4610.2006.00301.X |
| P698 | PubMed publication ID | 16412161 |
| P2093 | author name string | Peter J Goadsby | |
| Roger Yates | |||
| P2860 | cites work | Lost Productive Time and Cost Due to Common Pain Conditions in the US Workforce | Q45135661 |
| Treatment preferences and the selection of acute migraine medications: results from a population-based survey | Q46077712 | ||
| How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians | Q46422796 | ||
| Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers | Q49088816 | ||
| Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study. | Q50868159 | ||
| Work-related disability: results from the American migraine study. | Q51011782 | ||
| Effect of hepatic impairment on the pharmacokinetics of zolmitriptan. | Q53946789 | ||
| The global burden of disease study: implications for neurology | Q28138436 | ||
| Clinical efficacy and tolerability of sumatriptan tablet and suppository in the acute treatment of migraine: a review of data from clinical trials | Q30664337 | ||
| Prevalence and burden of migraine in the United States: data from the American Migraine Study II. | Q31974113 | ||
| Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies | Q33792830 | ||
| The pharmacology of headache | Q33952000 | ||
| Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials | Q34154647 | ||
| A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method | Q34357235 | ||
| Symptomatic and nonsymptomatic headaches in a general population | Q34435464 | ||
| Migraine--current understanding and treatment | Q34504002 | ||
| The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. | Q34536700 | ||
| The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers | Q34738942 | ||
| The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). | Q34741307 | ||
| Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans | Q35091964 | ||
| The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90) | Q36094218 | ||
| Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. | Q36723711 | ||
| What do patients with migraine want from acute migraine treatment? | Q39408073 | ||
| Determinants of patient satisfaction with migraine therapy | Q39424833 | ||
| Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat | Q39443442 | ||
| Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types | Q39446271 | ||
| Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine | Q39448115 | ||
| Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies | Q39452003 | ||
| Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Subcutaneous Alniditan Study Group. | Q39461265 | ||
| Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice | Q39463122 | ||
| Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients | Q39464740 | ||
| A nationwide survey of migraine in France: prevalence and clinical features in adults. GRIM | Q41823868 | ||
| The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial | Q43725563 | ||
| Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose-response study | Q44057662 | ||
| The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects | Q44075843 | ||
| Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers | Q44202476 | ||
| Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers | Q44202479 | ||
| The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate | Q44399050 | ||
| The truth about frovatriptan | Q44465539 | ||
| Meta-analysis methodology: the battle continues | Q44663016 | ||
| P433 | issue | 1 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 138-149 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Headache | Q5689497 |
| P1476 | title | Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy | |
| P478 | volume | 46 |
| Q37080223 | A Neurologist's Guide to Acute Migraine Therapy in the Emergency Room |
| Q47832688 | A coupled bimodal SPECT-CT imaging and brain kinetics studies of zolmitriptan-encapsulated nanostructured polymeric carriers |
| Q38539637 | A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine |
| Q47749005 | A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine |
| Q39366862 | AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine |
| Q38866983 | Acute, transitional and long-term cluster headache treatment: pharmacokinetic issues |
| Q38733029 | Autoradiographic Mapping of 5-HT(1B/1D) Binding Sites in the Rhesus Monkey Brain Using [carbonyl-C]zolmitriptan |
| Q38136260 | Breath powered nasal delivery: a new route to rapid headache relief |
| Q36641577 | Evidence-based understanding of medication-overuse headache: clinical implications |
| Q56893840 | From nose to brain: understanding transport capacity and transport rate of drugs |
| Q91627928 | In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug |
| Q38150429 | Insights into direct nose to brain delivery: current status and future perspective |
| Q39282412 | Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study |
| Q38136259 | Intranasal zolmitriptan for the treatment of acute migraine |
| Q41619376 | Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy |
| Q44679946 | Organic cation transporters in human nasal primary culture: expression and functional activity |
| Q37064080 | Pharmacogenomics and migraine: possible implications |
| Q43921835 | Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines |
| Q38674724 | Population Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With Migraine. |
| Q43286999 | Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device |
| Q37340160 | The pharmacological management of migraine, part 1: overview and abortive therapy |
| Q38690933 | Zolmitriptan Nasal Spray: A Review in Acute Migraine in Pediatric Patients 12 Years of Age or Older |
Search more.